Michael Bigham - Feb 2, 2018 Form 4 Insider Report for Paratek Pharmaceuticals, Inc. (PRTK)

Role: Exec. Chairman of the Board, Director
Signature: /s/ William M. Haskel, Attorney-in-Fact for Michael Bigham
Stock symbol: PRTK
Transactions as of: Feb 2, 2018
Transactions value $: $99,997
Form type: 4
Date filed: 9/21/2023, 01:18 PM
Next filing: Jun 8, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRTK	Common Stock	Options Exercise	$100K	+23.3K	+1.74%	$4.30^*	1.36M	Feb 2, 2018	Direct	F1, F2
transaction	PRTK	Common Stock	Disposed to Issuer		-1.13M	-83.16%		229K	Sep 21, 2023	Direct	F3, F4
transaction	PRTK	Common Stock	Disposed to Issuer		-229K	-100%		0	Sep 21, 2023	Direct	F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRTK	Stock Option (right to buy)	Options Exercise	$0	-23.2K	-100%	$0.00^*	0	Feb 2, 2018	Common Stock	23.3K	$4.30	Direct	F1, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Michael Bigham is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	This item reports the acquisition of 23,255 shares of the Issuer by the Reporting Person from the exercise of a stock option on February 2, 2018, which was previously not reported due to an administrative error.
F2	Due to administrative error, the Reporting Person's previous Form 4 filings under-reported the securities beneficially owned by the Reporting Person by 75 shares of common stock of the Issuer. This filing corrects such error and lists the correct amount of securities beneficially owned directly by the Reporting Person.
F3	This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash,
F4	(Continued from Footnote 3) without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC.
F5	Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration,
F6	(Continued from Footnote 5) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. If provided for pursuant to a subscription agreement entered into among the Reporting Person, the Issuer and Resistance TopCo L.P., a Delaware limited partnership ("Topco LP"), the settlement of such Equity Award Consideration may also be made inequity interests of Topco LP.
F7	The options vested as to 25% on January 1, 2016 and the remaining 75% of the award vested in a series of thirty-six successive equal monthly installments measured from January 1, 2016, subject generally to the Reporting Person's continued employment with the Issuer. After the Reporting Person's February 2, 2018 exercise, the remaining options were subsequently cancelled by the Issuer for no consideration.